.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical data explores the immunogenicity of Ozoralizumab in Rheumatoid Arthritis, focusing on anti-drug antibodies (ADA) and neutralizing antibodies (NAb). Ozoralizumab is a trivalent anti-TNFα Nanobody designed to treat RA effectively. However, antibody development can sometimes impact therapeutic outcomes. Consequently, researchers evaluated results from the OHZORA and NATSUZORA trials to assess these impacts. The analysis specifically looked at safety, treatment continuation, and long-term efficacy.
The study noted ADA induction in 29.2% of patients receiving methotrexate. In contrast, patients without methotrexate showed a higher induction rate of 44.3%. Nevertheless, ADA presence did not compromise safety or lead to treatment discontinuation. This suggests that ADA formation alone is not a primary concern for clinicians managing RA. Instead, the focus remains on the specific neutralizing potential of these antibodies.
NAb expression remained significantly lower in patients using methotrexate concurrently. In the NATSUZORA trial, NAb-positive participants experienced a reduction in efficacy. However, nearly half of these patients still maintained low disease activity. Furthermore, the OHZORA trial demonstrated that Ozoralizumab in Rheumatoid Arthritis maintains efficacy despite NAb presence when paired with methotrexate. Therefore, methotrexate co-administration plays a vital role in antibody suppression and drug performance.
Long-term data from the HOSHIZORA extension trial showed sustained disease control for many participants. Even NAb-positive individuals showed clinical benefits over the extended treatment period. These findings provide reassurance regarding the long-term use of this novel trivalent Nanobody. Clinicians should prioritize methotrexate co-administration to optimize the treatment's safety and effectiveness. Moreover, monitoring NAb status may help tailor individual therapy for patients with inadequate responses.
Clinical trials indicate that ADA induction does not negatively impact the safety profile or the continuation of Ozoralizumab treatment in most patients.
Co-administering methotrexate reduces the development of neutralizing antibodies (NAb). This helps maintain the long-term clinical efficacy and safety of Ozoralizumab in Rheumatoid Arthritis.
Yes, data shows that approximately half of NAb-positive patients can still maintain low disease activity, particularly when receiving long-term maintenance therapy.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.
References
Kawanishi M et al. Impact of Anti-Drug Antibodies and Neutralising Antibodies on Safety and Efficacy of Ozoralizumab in Rheumatoid Arthritis. Mod Rheumatol. 2026 Feb 20. doi: undefined. PMID: 41717779.
Duggan S. Ozoralizumab: First Approval. Drugs. 2022;82(17):1683-1688.
Tanaka Y. Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis. Expert Opin Biol Ther. 2023;23(7):579-587.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New data reveals how anti-drug and neutralizing antibodies affect Ozoralizumab's performance in RA and how methotrexate helps maintain clinical outcomes....
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
